Zoledronic acid 4 mg/5 ml

Metadronic (Zoledronic acid) demonstrated efficacy in the reduction of Skeletal Related Events (SREs) in patients with multiple myeloma or bone metastases secondary to breast cancer, prostate cancer or other solid tumors, or Hypercalcaemia of Malignancy (HCM).

For more information about this product click on the links below:

+ Professionals

+ Consumer

+ Diseases & conditions

Copyright © 2017 Global Napi Pharmaceuticals.All rights reserved.
Designed & Developed by | VisionApps Team.